ArticleBlood2022
Incidence and impact of anticoagulation-associated abnormal menstrual bleeding in women after venous thromboembolism.
Article in Blood, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04748393 (Risk, Predictors, Impact and Outcome of Anticoagulation-associated Abnormal Menstrual Bleeding in Female Patients With VTE), which is not on this map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Risk, Predictors, Impact and Outcome of Anticoagulation-associated Abnormal Menstrual Bleeding in Female Patients With VTE
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Interdisciplinary management of gynecologic bleeding with anticoagulation: a recommended toolkit from the Foundation for Women and Girls with Blood Disorders+ Thrombosis Subcommittee.Journal of thrombosis and haemostasis : JTH · 2025Guideline
- Updated guidance for efficacy and safety outcomes for clinical trials in venous thromboembolism in children: communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis.Journal of thrombosis and haemostasis : JTH · 2023Guideline
- Heavy Menstrual Bleeding in Women Treated with Direct Oral Anticoagulants: Results of the Prospective HEMBLED Registry.Thrombosis and haemostasis · 2026Trial
- Anticoagulants beyond coagulation: a narrative review of cardiovascular effects.Cardiovascular research · 2026Review
- Sex Differences in Cancer-Associated Thrombosis.International journal of molecular sciences · 2026Review
- Prevalence of abnormal uterine bleeding and quality of life after venous thromboembolism by oral anticoagulant use: the GENB-OAC Study.Research and practice in thrombosis and haemostasis · 2026Article
- Patient-centered management of heavy menstrual bleeding while on anticoagulation: A survey study.European journal of obstetrics, gynecology, and reproductive biology · 2025Article
- Menstrual bleeding-specific quality of life in women on antiplatelet therapy.Research and practice in thrombosis and haemostasis · 2025Article
- Facilitating active participation in anticoagulant decisions in advanced kidney disease: co-production of a question prompt list.BMC nephrology · 2025Article
- Hormone-related thrombosis: duration of anticoagulation, risk of recurrence, and the role of hypercoagulability testing.Hematology. American Society of Hematology. Education Program · 2024Review
- Syndemics in women's health: poverty, social exclusion, and clustering of thrombotic and hemostasis disorders.Research and practice in thrombosis and haemostasis · 2024Article
- Heavy menstrual bleeding on direct factor Xa inhibitors: the MEDEA randomized clinical trial.Research and practice in thrombosis and haemostasis · 2024Article
- Review
- Qualitative experiences, values, and decisional needs of patients with unprovoked venous thromboembolism who suffer bleeding-"This pill will keep you alive tonight".Research and practice in thrombosis and haemostasis · 2024Article
- Effects of antiplatelet therapy on menstrual blood loss in reproductive-aged women: a systematic review.Research and practice in thrombosis and haemostasis · 2024Article
- Antiplatelet period drama: a rush of blood or classic crimson tide?Research and practice in thrombosis and haemostasis · 2024Article
- The "Research and practice in thrombosis and haemostasis · 2023Article
- How do anticoagulants impact menstrual bleeding and quality of life? - The PERIOD study.Research and practice in thrombosis and haemostasis · 2023Article
- Editorial: Venous thromboembolism and pregnancy.Frontiers in cardiovascular medicine · 2022Article
- Pharmacists' Knowledge of Abnormal Uterine Bleeding in Women on Anticoagulant Therapy: A French Survey.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
18 authors at 11 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preliminary data and clinical experience have suggested an increased risk of abnormal uterine bleeding (AUB) in women of reproductive age treated with anticoagulants, but solid data are lacking. The TEAM-VTE study was an international multicenter prospective cohort study in women aged 18 to 50 years diagnosed with acute venous thromboembolism (VTE). Menstrual blood loss was measured by pictorial blood loss assessment charts at baseline for the last menstrual cycle before VTE diagnosis and prospectively for each cycle during 3 to 6 months of follow-up. AUB was defined as an increased score on the pictorial blood loss assessment chart (>100 or >150) or self-reported AUB. AUB-related quality of life (QoL) was assessed at baseline and the end of follow-up using the Menstrual Bleeding Questionnaire. The study was terminated early because of slow recruitment attributable to the COVID-19 pandemic. Of the 98 women, 65 (66%) met at least one of the 3 definitions of AUB during follow-up (95% confidence interval [CI], 57%-75%). AUB occurred in 60% of women (36 of 60) without AUB before VTE diagnosis (new-onset AUB; 95% CI, 47%-71%). Overall, QoL decreased over time, with a mean Menstrual Bleeding Questionnaire score increase of 5.1 points (95% CI, 2.2-7.9), but this decrease in QoL was observed only among women with new-onset AUB. To conclude, 2 of every 3 women who start anticoagulation for acute VTE experience AUB, with a considerable negative impact on QoL. These findings should be a call to action to increase awareness and provide evidence-based strategies to prevent and treat AUB in this setting. This was an academic study registered at www.clinicaltrials.gov as #NCT04748393; no funding was received.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.